DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

DBV Technologies S.A. (NASDAQ:DBVT) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $48.50.

Several equities analysts recently weighed in on DBVT shares. Citizens Jmp increased their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th.

DBV Technologies Stock Up 3.1%

Shares of DBVT opened at $16.54 on Friday. DBV Technologies has a 12-month low of $8.50 and a 12-month high of $26.18. The firm has a market capitalization of $979.33 million, a PE ratio of -3.71 and a beta of -0.99. The stock’s fifty day simple moving average is $19.48 and its 200-day simple moving average is $19.65.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. Analysts anticipate that DBV Technologies will post -0.47 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new position in DBV Technologies in the first quarter valued at about $20,146,000. Vivo Capital LLC lifted its stake in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the 1st quarter valued at approximately $21,159,000. Royal Bank of Canada raised its position in shares of DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after acquiring an additional 2,928 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies in the 1st quarter valued at approximately $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.